缺铁性贫血治疗市场报告：2030 年趋势、预测与竞争分析

缺铁性贫血治疗的趋势与预测

预计到 2030 年，全球缺铁性贫血治疗市场将达到约 46 亿美元，2024 年至 2030 年复合年增长率为 5.3%。该市场的主要驱动因素是缺铁性贫血的高发病率，特别是影响妇女和儿童，这是由于食品中铁摄入不足和红血球过度消耗所致，女性人口迅速增加，女性健康意识不断增强； 。全球缺铁性贫血治疗市场的未来看起来充满希望，医院、诊所和居家医疗市场都充满机会。

缺铁性贫血治疗市场洞察

Lucintel 预测，由于接受重组促促血红细胞生长素治疗的患者和患有阻碍口服铁吸收的慢性疾病的患者的高需求，肠外铁剂治疗将在整个预测期内保持最大的份额。

医院将继续成为该市场中最大的部分，因为它们有更好的能力来处理复杂的病例，并拥有管理患者所需的设施和人员。

由于医疗保健支出迅速增加、人口中缺铁性贫血盛行率增加以及该地区主要市场参与者的存在，预计北美在整个预测期内仍将是最大的地区。

常问问题

Q1.市场规模为：

A1. 到 2030 年，全球缺铁性贫血治疗市场预计将达到 46 亿美元。

Q2.市场成长预测是多少：

A2. 2024年至2030年，全球缺铁性贫血治疗市场预计将以5.3%的复合年增长率成长。

Q3.影响市场成长的主要驱动因素是：

A3. 该市场的主要驱动因素是缺铁性贫血的高发，由于食品中铁摄入不足和红血球过度减少，缺铁性贫血尤其影响妇女和儿童；这是由于人们对缺铁性贫血的认识迅速提高。

Q4.市场的主要细分市场是：

A4. 全球缺铁性贫血治疗市场前景广阔，医院、诊所和居家医疗市场充满机会。

Q5.市场的主要企业是：

A5.主要的缺铁性贫血治疗公司如下。

• Abbvie
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Pharmacosmos
• Sanofi
• Johnson and Johnson
• Fresenius
• ViforPharma
• Rockwell Medical

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计，由于接受重组促促血红细胞生长素治疗的患者以及患有阻碍口服铁吸收的慢性疾病的患者的需求量很大，因此在整个预测期内，肠外铁剂治疗仍将是最大的部分。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 由于医疗保健成本迅速上升、人口中缺铁性贫血的盛行率增加以及该地区主要市场参与者的存在，预计北美在整个预测期内仍将是最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球缺铁性贫血治疗市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球缺铁性贫血治疗市场趋势（2018-2023）与预测（2024-2030）
• 按治疗方法的全球缺铁性贫血治疗市场
  • 口服铁剂疗法
  • 肠外铁剂治疗
  • 红血球输注
• 全球缺铁性贫血治疗市场（依最终用途）
  • 医院
  • 诊所
  • 居家医疗

第四章 2018-2030年区域市场趋势及预测分析

• 全球缺铁性贫血治疗市场（按地区）
• 北美缺铁性贫血治疗市场
• 欧洲缺铁性贫血治疗市场
• 亚太地区缺铁性贫血治疗市场
• 其他地区缺铁性贫血治疗市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球缺铁性贫血治疗市场成长机会（依治疗方法）
  • 全球缺铁性贫血治疗市场成长机会（依最终用途）
  • 全球缺铁性贫血治疗市场按地区成长机会
• 全球缺铁性贫血治疗市场的新趋势
• 战略分析
  • 新产品开发
  • 扩大全球缺铁性贫血治疗市场的产能
  • 全球缺铁性贫血治疗市场的併购与合资企业
  • 认证和许可

第七章主要企业概况

• Abbvie
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Pharmacosmos
• Sanofi
• Johnson and Johnson
• Fresenius
• ViforPharma
• Rockwell Medical

Iron Deficiency Anemia Therapy Trends and Forecast

The future of the global iron deficiency anemia therapy market looks promising with opportunities in the hospital, clinic, and home healthcare markets. The global iron deficiency anemia therapy market is expected to reach an estimated $4.6 billion by 2030 with a CAGR of 5.3% from 2024 to 2030. The major drivers for this market are high incidence of iron deficiency anemia is attributed to insufficient iron intake from food and excessive loss of red blood cells, particularly affecting women and children, surge in female population, and growing awareness towards women health.

A more than 150-page report is developed to help in your business decisions.

Iron Deficiency Anemia Therapy by Segment

The study includes a forecast for the global iron deficiency anemia therapy by therapy type, end use, and region.

Iron Deficiency Anemia Therapy Market by Therapy Type [Shipment Analysis by Value from 2018 to 2030]:

• Oral Iron Therapy
• Parenteral Iron Therapy
• Red Blood Cell Transfusion

Iron Deficiency Anemia Therapy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Clinics
• Home Healthcare

Iron Deficiency Anemia Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Iron Deficiency Anemia Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies iron deficiency anemia therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the iron deficiency anemia therapy companies profiled in this report include-

• Abbvie
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Pharmacosmos
• Sanofi
• Johnson and Johnson
• Fresenius
• ViforPharma
• Rockwell Medical

Iron Deficiency Anemia Therapy Market Insights

Lucintel forecasts that parenteral iron therapy will remain the largest segment over the forecast period due to high demand for patients receiving recombinant erythropoietin therapy or suffering from chronic diseases that hinder iron absorption through oral means.

Within this market, hospital will remain the largest segment as it is equipped to handle complex cases and has necessary facilities and staffs to manage patients.

North America will remain the largest region over the forecast period due to surge in healthcare spending, increasing prevalence of iron deficiency anemia among the population, and the presence of key market players in the region.

Features of the Global Iron Deficiency Anemia Therapy Market

Market Size Estimates: Iron deficiency anemia therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Iron deficiency anemia therapy market size by therapy type, end use, and region in terms of value ($B).

Regional Analysis: Iron deficiency anemia therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapy types, end uses, and regions for the iron deficiency anemia therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the iron deficiency anemia therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the iron deficiency anemia therapy market size?

Answer: The global iron deficiency anemia therapy market is expected to reach an estimated $4.6 billion by 2030.

Q2. What is the growth forecast for iron deficiency anemia therapy market?

Answer: The global iron deficiency anemia therapy market is expected to grow with a CAGR of 5.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the iron deficiency anemia therapy market?

Answer: The major drivers for this market are high incidence of iron deficiency anemia is attributed to insufficient iron intake from food and excessive loss of red blood cells, particularly affecting women and children, surge in female population, and growing awareness towards women health.

Q4. What are the major segments for iron deficiency anemia therapy market?

Answer: The future of the global iron deficiency anemia therapy market looks promising with opportunities in the hospital, clinic, and home healthcare markets.

Q5. Who are the key iron deficiency anemia therapy market companies?

Answer: Some of the key iron deficiency anemia therapy companies are as follows:

• Abbvie
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Pharmacosmos
• Sanofi
• Johnson and Johnson
• Fresenius
• ViforPharma
• Rockwell Medical

Q6. Which iron deficiency anemia therapy market segment will be the largest in future?

Answer: Lucintel forecasts that parenteral iron therapy will remain the largest segment over the forecast period due to high demand for patients receiving recombinant erythropoietin therapy or suffering from chronic diseases that hinder iron absorption through oral means.

Q7. In iron deficiency anemia therapy market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to surge in healthcare spending, increasing prevalence of iron deficiency anemia among the population, and the presence of key market players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the iron deficiency anemia therapy market by therapy type (oral iron therapy, parenteral iron therapy, and red blood cell transfusion), end use (hospitals, clinics, and home healthcare), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Iron Deficiency Anemia Therapy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Iron Deficiency Anemia Therapy Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Iron Deficiency Anemia Therapy Market by Therapy Type
  • 3.3.1: Oral Iron Therapy
  • 3.3.2: Parenteral Iron Therapy
  • 3.3.3: Red Blood Cell Transfusion
• 3.4: Global Iron Deficiency Anemia Therapy Market by End Use
  • 3.4.1: Hospitals
  • 3.4.2: Clinics
  • 3.4.3: Home Healthcare

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Iron Deficiency Anemia Therapy Market by Region
• 4.2: North American Iron Deficiency Anemia Therapy Market
  • 4.2.2: North American Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare
• 4.3: European Iron Deficiency Anemia Therapy Market
  • 4.3.1: European Iron Deficiency Anemia Therapy Market by Therapy Type: Oral Iron Therapy, Parenteral Iron Therapy, and Red Blood Cell Transfusion
  • 4.3.2: European Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare
• 4.4: APAC Iron Deficiency Anemia Therapy Market
  • 4.4.1: APAC Iron Deficiency Anemia Therapy Market by Therapy Type: Oral Iron Therapy, Parenteral Iron Therapy, and Red Blood Cell Transfusion
  • 4.4.2: APAC Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare
• 4.5: ROW Iron Deficiency Anemia Therapy Market
  • 4.5.1: ROW Iron Deficiency Anemia Therapy Market by Therapy Type: Oral Iron Therapy, Parenteral Iron Therapy, and Red Blood Cell Transfusion
  • 4.5.2: ROW Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Iron Deficiency Anemia Therapy Market by Therapy Type
  • 6.1.2: Growth Opportunities for the Global Iron Deficiency Anemia Therapy Market by End Use
  • 6.1.3: Growth Opportunities for the Global Iron Deficiency Anemia Therapy Market by Region
• 6.2: Emerging Trends in the Global Iron Deficiency Anemia Therapy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Iron Deficiency Anemia Therapy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Iron Deficiency Anemia Therapy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbvie
• 7.2: Akebia Therapeutics
• 7.3: AMAG Pharmaceuticals
• 7.4: Daiichi Sankyo
• 7.5: Pharmacosmos
• 7.6: Sanofi
• 7.7: Johnson and Johnson
• 7.8: Fresenius
• 7.9: ViforPharma
• 7.10: Rockwell Medical